Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Tumors × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 136 Colorectal Neoplasms 72 Stomach Neoplasms 67 Neoplasms 33 Neoplasm Metastasis 33 Pancreatic Neoplasms 22 Triple Negative Breast Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 12 Esophageal Neoplasms 12 Adenocarcinoma 11 Rectal Neoplasms 9 Colonic Neoplasms 9 Brain Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Carcinoma, Hepatocellular 7 Biliary Tract Neoplasms 7 Adenocarcinoma Of Esophagus 7 Cholangiocarcinoma 6 Solid Tumor 5 Ovarian Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Nasopharyngeal Carcinoma 4 Gastrointestinal Neoplasms 4 Nasopharyngeal Neoplasms 3 Head and Neck Neoplasms 3 Gallbladder Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3

Interventions

camrelizumab 1 Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡